@article{da6a37b4eef24191a8030a176d14d01a,
title = "In Reply re: {"}Comparison of F(ab')2 versus Fab antivenom for Pit Viper Envenomation: A Prospective, Blinded, Multicenter, Randomized Clinical Trial{"}",
author = "Bush, \{Sean P.\} and Ruha, \{Anne Michelle\} and Seifert, \{Steven A.\} and Sollee, \{Dawn R.\} and Boyer, \{Leslie V.\}",
note = "Funding Information: Rare Disease Therapeutics, Inc. (RDT) sponsored this study through contracts with the authors {\textquoteright} affiliated institutions, and Instituto Bioclon, SA de CV provided the F(ab {\textquoteright} ) 2 antivenom for this study. The authors report remuneration for educational presentations from BTG international Inc (BTG) (SPB, AMR) and from RDT (AMR); participation in an expert panel sponsored by BTG that developed a treatment algorithm for pit viper envenomation (SPB, AMR, SAS); being investigators in phase 2 and/or phase 3 clinical trials of a black widow spider antivenom manufactured by Instituto Bioclon, under contract with Rocky Mountain Poison \& Drug Center (SPB, AMR, SAS); being investigators in phase 2 and/or phase 3 clinical trials of a scorpion antivenom manufactured by Instituto Bioclon (AMR, LVB); and receiving a contract from Instituto Bioclon for development of North African antivenom (LVB).",
year = "2015",
month = may,
day = "1",
doi = "10.3109/15563650.2015.1016167",
language = "English (US)",
volume = "53",
pages = "414--415",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Taylor and Francis Ltd.",
number = "4",
}